Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2012 1
2013 1
2014 1
2015 1
2018 3
2019 2
2020 1
2021 4
2022 3
2023 5
2024 4
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Among authors: eichenbaum da. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Khanani AM, et al. Among authors: eichenbaum da. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. Lancet. 2023. PMID: 37696275
Correspondence.
Davis A, Cohen SM, Pautler SE, Billiris-Findlay K, Eichenbaum DA. Davis A, et al. Among authors: eichenbaum da. Retina. 2013 Nov-Dec;33(10):2185. doi: 10.1097/IAE.0b013e31829f731e. Retina. 2013. PMID: 23903791 No abstract available.
Evolving Guidelines for Intracameral Injection.
Liebmann JM, Barton K, Weinreb RN, Eichenbaum DA, Gupta PK, McCabe CM, Wolfe JD, Ahmed I, Sheybani A, Craven ER. Liebmann JM, et al. Among authors: eichenbaum da. J Glaucoma. 2020 Mar;29 Suppl 1:S1-S7. doi: 10.1097/IJG.0000000000001451. J Glaucoma. 2020. PMID: 31977546 Review.
Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial.
Bressler SB, Barve A, Ganapathi PC, Beckmann K, Apte RS, Marcus DM, Baumane K, Agarwal S, Oleksy P, Reichstein DA, Patel SS, Ernest J, Dégi R, Gupta V, Kishino G, Kamei M, Loganathan S; INSIGHT Study Group. Bressler SB, et al. JAMA Ophthalmol. 2024 Oct 1;142(10):952-960. doi: 10.1001/jamaophthalmol.2024.3458. JAMA Ophthalmol. 2024. PMID: 39264599 Free PMC article. Clinical Trial.
Biosimilars in the Treatment of Retinal Disease in the United States.
Vakharia PS, Eichenbaum DA, Baumal CR. Vakharia PS, et al. Among authors: eichenbaum da. Ophthalmic Surg Lasers Imaging Retina. 2023 Jun;54(6):362-366. doi: 10.3928/23258160-20230508-01. Epub 2023 Jan 5. Ophthalmic Surg Lasers Imaging Retina. 2023. PMID: 37222553 Review.
Angiopoietins as Potential Targets in Management of Retinal Disease.
Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, Singh RP. Khanani AM, et al. Among authors: eichenbaum da. Clin Ophthalmol. 2021 Sep 4;15:3747-3755. doi: 10.2147/OPTH.S231801. eCollection 2021. Clin Ophthalmol. 2021. PMID: 34511878 Free PMC article. Review.
31 results